Literature DB >> 25819867

Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A.

Philippe Andre1, Stéphane Schneebeli2, Corinne Vigouroux3, Olivier Lascols3, Mathieu Schaaf4, Philippe Chevalier4.   

Abstract

BACKGROUND: Laminopathies are associated with a broad spectrum of clinical manifestations, from lipodystrophy to cardiac diseases. The purpose of this study was to assess genotype-phenotype correlations in a lipodystrophic laminopathy caused by the Lamin A (LMNA) mutation T655fsX49. This mutation leads to synthesis of nonfarnesylated-mutated prelamin A that does not undergo the physiologic lamin A maturation process. METHODS AND
RESULTS: We studied 35 patients originating from Reunion Island who carried the LMNA T655fsX49 mutation. Comparisons of cardiac and endocrinologic features were made between homozygous and heterozygous patients. Homozygous patients presented more overlapping syndromes with severe cardiac phenotypes, defined by cardiolaminopathy, early atheroma with coronary heart disease (CHD) and high-degree conduction disorder compared with heterozygous (40% vs 4%; P = .016). Moreover, homozygous patients had earlier onset (49.6 vs 66 years old; P = .0002). Left ventricle lowered ejection fraction associated with heart failure was more frequent in homozygous than in heterozygous patients (40% vs 0%, respectively). Lipodystrophic traits were more marked in the homozygous group but only reached statistical significance for L4 subcutaneous fat measurement (2.8 ± 2.16 vs 18.7 ± 8.9 mm; P = .008) and leptin levels (2.45 ± 1.6 vs 11.26 ± 7.2 ng/mL; P = .0001).
CONCLUSIONS: Our results suggest that there is a relationship between mutated prelamin-A accumulation and the severity of the phenotypes in homozygous familial partial lipodystrophy type 2 patients who harbor the LMNA T655fsX49 mutation. A dose-dependent effect seems likely.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25819867     DOI: 10.1016/j.ahj.2014.12.021

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

1.  Clinical Utility Gene Card for: Familial partial lipodystrophy.

Authors:  Isabelle Jéru; Camille Vatier; David Araujo-Vilar; Corinne Vigouroux; Olivier Lascols
Journal:  Eur J Hum Genet       Date:  2016-08-03       Impact factor: 4.246

Review 2.  Lipodystrophy for the Diabetologist-What to Look For.

Authors:  Nivedita Patni; Abhimanyu Garg
Journal:  Curr Diab Rep       Date:  2022-07-11       Impact factor: 5.430

Review 3.  Recent advances in animal and human pluripotent stem cell modeling of cardiac laminopathy.

Authors:  Yee-Ki Lee; Yu Jiang; Xin-Ru Ran; Yee-Man Lau; Kwong-Man Ng; Wing-Hon Kevin Lai; Chung-Wah Siu; Hung-Fat Tse
Journal:  Stem Cell Res Ther       Date:  2016-09-20       Impact factor: 6.832

Review 4.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

Review 5.  Current insights into LMNA cardiomyopathies: Existing models and missing LINCs.

Authors:  Daniel Brayson; Catherine M Shanahan
Journal:  Nucleus       Date:  2017-01-02       Impact factor: 4.197

6.  Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy.

Authors:  Utku Erdem Soyaltin; Ilgin Yildirim Simsir; Baris Akinci; Canan Altay; Suleyman Cem Adiyaman; Kristen Lee; Huseyin Onay; Elif Arioglu Oral
Journal:  Clin Diabetes Endocrinol       Date:  2020-07-14

7.  Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred.

Authors:  Renan Magalhães Montenegro; Aline Dantas Costa-Riquetto; Virgínia Oliveira Fernandes; Ana Paula Dias Rangel Montenegro; Lucas Santos de Santana; Alexander Augusto de Lima Jorge; Lia Beatriz de Azevedo Souza Karbage; Lindenberg Barbosa Aguiar; Francisco Herlânio Costa Carvalho; Milena Gurgel Teles; Catarina Brasil d'Alva
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-20       Impact factor: 5.555

8.  Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.

Authors:  My-Le Nguyen; Vandana Sachdev; Thomas R Burklow; Wen Li; Megan Startzell; Sungyoung Auh; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

9.  A Heterozygous ZMPSTE24 Mutation Associated with Severe Metabolic Syndrome, Ectopic Fat Accumulation, and Dilated Cardiomyopathy.

Authors:  Damien Galant; Bénédicte Gaborit; Camille Desgrouas; Ines Abdesselam; Monique Bernard; Nicolas Levy; Françoise Merono; Catherine Coirault; Patrice Roll; Arnaud Lagarde; Nathalie Bonello-Palot; Patrice Bourgeois; Anne Dutour; Catherine Badens
Journal:  Cells       Date:  2016-04-25       Impact factor: 6.600

Review 10.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.